| Title |
Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, December 2016
|
| DOI | 10.1007/s00280-016-3213-5 |
| Pubmed ID | |
| Authors |
Jan S. Moreb, Deniz A. Ucar-Bilyeu, Abdullah Khan |
| Abstract |
A large number of studies have investigated possible drug resistance mechanisms of cancer cells and suggested strategies to overcome it. In this review, we outline the role and function of aldehyde dehydrogenase (ALDH) activity in multiple cellular functions and in cancer stem cells (CSCs) and focus on the role of retinoic acid (RA), one of the products of ALDH isozymes. We discuss our observation that ATRA and other RAs can suppress ALDH activity and decrease different ALDH isozyme proteins and result in detrimental effects on cell proliferation, invasion and chemotherapy sensitivity. We review the known uses of different RAs in the treatment of cancers. We review the use of RAs in combination with chemo-/radiotherapy and the major signaling pathways affected in different tumor types. We provide follow-up on studies that may have used our prior observation with the aim of targeting the CSCs. We conclude with summary of the findings and potential impact of published studies on future use of RAs in the targeting of CSCs and drug resistance. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 64 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 14 | 22% |
| Researcher | 9 | 14% |
| Student > Master | 9 | 14% |
| Student > Bachelor | 6 | 9% |
| Student > Doctoral Student | 4 | 6% |
| Other | 10 | 16% |
| Unknown | 12 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 25% |
| Biochemistry, Genetics and Molecular Biology | 14 | 22% |
| Agricultural and Biological Sciences | 4 | 6% |
| Immunology and Microbiology | 3 | 5% |
| Chemistry | 3 | 5% |
| Other | 8 | 13% |
| Unknown | 16 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 December 2016.
All research outputs
#21,164,509
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#2,211
of 2,501 outputs
Outputs of similar age
#358,274
of 423,824 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#16
of 19 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 423,824 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.